I-SOL: New broad-spectrum antiviral therapy

Novel recombinant protein based on sIFNAR2 (I-SOL), a soluble isoform of IFN-β, which possesses antiviral activity.

IFN-ß is a cytokine that mediates a variety of biological responses, including antiviral, antiproliferative and immunomodulatory effects. As a result, I-SOL exhibits activity on its own producing the same responses that IFN-ß mediates**.**

Results

The antiviral activity has been tested by bioassay in three independent laboratories. Currently, more than 40 tests have been performed to validate the activity on different viruses, such as: HIV, SARS-CoV-2 or respiratory syncytial virus.

In vitro and in vivo toxicity studies are also available.